/
Other
Inflammation
30
Pipeline Programs↗
58
Active Trials↗
35
Companies Involved↗
Inflammation is an emerging landscape with 30 programs across 35 companies. The most active players are Verona Pharma plc. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical13
Phase 12
Phase 214
Approved
No programs
Analysis
Modality Breakdown
86%
Small molecule
25 of 29 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 29 classified programs, each share of the total. Modality classified for 97% of 30 pipeline programs.
Analysis
Trial Status
314
clinical trials
Completed193 · 61%
Recruiting36 · 11%
Unknown status28 · 9%
Terminated19 · 6%
Withdrawn14 · 4%
Not yet recruiting9 · 3%
Other15 · 5%
Clinical Trials
Trial Activity
314 trials
Diagnosis and Management of Inflammatory and Infectious Diseases
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00557726·400 enrolled
Natural History of The Human Biological Response to Environmental Exposure and Injury
Recruiting·National Institute of Environmental Health Sciences (NIEHS)·N/A·NCT04888923·2,000 enrolled
Natural History of Inflammatory Muscle Diseases
Recruiting·National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)·N/A·NCT05738824·500 enrolled
Page 1 of 21
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)